Various mutations in the genes encoding alpha spectrin (SPTA1) or beta spectrin (SPTB) are known to cause erythrocyte membrane disorders, sometimes associated with severe neonatal jaundice and anemia. We used a next-generation sequencing panel to evaluate 3 unrelated neonates who had puzzling cases of nonimmune hemolytic jaundice. In each case, we identified novel mutations in either SPTA1 or SPTB. Correlating erythrocyte morphology, clinical course, and computational analysis, we submit that each of the 3 variants is a probable pathogenic cause of the hereditary hemolytic conditions in these patients. We hope other pediatric practitioners caring for neonates with what appears to be idiopathic severe neonatal hyperbilirubinemia will look for spectrin variants as a possible cause, because additional cases with these specific variants along with this clinical phenotype are needed to confirm our postulate that these 3 cases are indeed pathogenic mutations.
Introduction
Severe neonatal hyperbilirubinemia can result in bilirubin-induced neurological dysfunction. 1 Unfortunately, the underlying causes of severe neonatal jaundice can go undiagnosed. 2 However, clearly identifying the underlying cause can be valuable, informing recurrence risks of future pregnancies, 3 and revealing the etiologies that are otherwise labeled as idiopathic neonatal jaundice. 4 Moreover, neonates with severe hemolytic jaundice are at subsequent risk for developing anemia and iron overload, whether or not they have frequent blood transfusions, because of compensatory erythropoietic stimulation through the erythroferrone/hepcidin axis. 5 Furthermore, chronic hemolysis can have the consequences of gallstones and parvovirus-induced aplastic crisis. 6 We provided care for 3 neonates who had severe and prolonged nonimmune jaundice and anemia where no underlying cause was initially identified. Red blood cell morphology was consistent with hereditary pyropoikilocytosis (HPP) in 1 neonate and with hereditary spherocytosis (HS) in the other 2 neonates. Next-generation DNA sequencing using a panel covering genes that are involved in hemolytic anemia and bilirubin metabolism (shown as Supplementary Material, available online at http://clp.sagepub.com/supplemental) revealed novel variants in SPTA1 in 2 cases and in SPTB in the third.
Here we report these variants and propose that they are likely causative of the hemolytic conditions in these 3 patients.
Clinical Report

Patient 1: Hereditary Pyropoikilocytosis Phenotype
This male was delivered vaginally at 40 weeks gestation to a healthy 28-year-old Caucasian G2 P1010 mother with a diagnosis of hereditary elliptocytosis. The mother, who is the only individual in her family with this diagnosis, had a cholecystectomy at age 7 years and is otherwise healthy. The father is African American and healthy with no personal or family history of anemia, jaundice, gallbladder disease, or splenectomy. Examination of his red cells reveals only rare elliptocytes (Table 1) . Apgar scores were 8 and 9, birth weight 3680 g. He was breastfeeding, appeared normal and healthy, and was cared for in the mother-baby unit. Twelve hours after birth his serum bilirubin was 12.8 mg/dL (>95th % on the hour-specific Bhutani nomogram), 7 and intensive phototherapy was initiated. His blood group was O positive, with a negative Coombs test. Mother was blood group A positive. His bilirubin increased to 13.6 mg/dL at 24 hours of age. Because of the rising bilirubin value under intensive phototherapy, he was transferred to the newborn care unit for monitoring, additional evaluation, and continued treatment. Phototherapy was continued and his bilirubin continued to rise slightly, then fell slowly over several days. On day of life 5 his end tidal carbon monoxide concentration (CoSense, Capnia, Inc, Redwood City, CA) was high (2.8 ppm, reference range for 7-day old, ≤1 ppm). 8 He was discharged home on day 7 with an indirect bilirubin of 8 mg/dL and a homephototherapy blanket.
His complete blood count (CBC) on discharge, and at 4 and 5 weeks, along with CBCs from father and mother, are shown in Table 1 . Photomicrographs of blood smears from the neonate and his parents on day 7 are shown in Figure 1A to C. Examination of the father's blood smear revealed a few scattered elliptocytes. Father's ETCOc was <1 ppm (normal). Mother had many elliptocytes and her ETCOc was 3.8 ppm (about 4 times normal). The neonate had a grossly abnormal red blood morphology with abundant microspherocytes, schistocytes, helmet-shaped cells, elliptocytes, and membrane budding, all consistent with HPP. At 2 and 7 days of age the neonate's hearing screen was reported to be normal. At 5 weeks he was transfused with 20 mL/kg donor red blood cells (RBC) for a low hematocrit.
Patient 2: Hereditary Spherocytosis Phenotype
This female was delivered vaginally to a healthy 32-year-old Caucasian G2P1001 at 39 6/7 weeks gestation. Apgar scores were 8 and 9, birth weight was 3090 g. She appeared well, had no dysmorphic features, and was breastfeeding in the mother-baby unit. Five hours after birth she was noted to be jaundiced and her bilirubin was 11.6 g/dL (>95th % on the hour-specific Bhutani nomogram 7 ), thus intensive phototherapy was initiated. Baby and mother were both blood group B positive and Coombs test was negative. As shown in Table 2 , the baby had a low hemoglobin (12.3 g/dL) and hematocrit (35.8%), with an elevated reticulocyte count (23%).
Because of a rising bilirubin value under intensive phototherapy she was transferred to the newborn care unit for monitoring, further evaluation, and treatment. Despite phototherapy her bilirubin continued to rise before falling slowly over several days. On the third day after birth, hemolysis was documented by an elevated end tidal carbon monoxide concentration of 4.9 ppm (reference range for 7-day old, ≤1 ppm), 8 and a haptoglobin below the lower limit of detection (<8 mg/dL). Her blood film (Figure 2 ) examination revealed abundant microspherocytes, nucleated red blood cells, and significant polychromasia.
She was discharged home with a home-phototherapy blanket on day 7 with a hematocrit 31.0%, hemoglobin 10.3 g/dL, mean corpuscular hemoglobin concentration (MCHC) 33.2 pg, mean corpuscular volume (MCV) 92.5 fL, and indirect bilirubin 10.0 mg/dL. The following week her hematocrit was 28.3%. Six weeks after birth her hematocrit was 31.0%, hemoglobin 10.3 g/dL, Figure 1 . Neonate with HPP. Photomicrographs of blood film from (A) father, (B) mother, and (C) neonate. Father has a few elliptocytes, the mother has many, and the neonate has a variety of abnormal shapes including microspherocytes, schistocytes, helmet cells, and elliptocytes. MCHC 33.2 g/dL, MCV 92.5 fL, reticulocyte count 2.8%. Blood film examination revealed persistent abundant spherocytes, with less polychromasia, no erythroblastosis or other morphological abnormalities.
Patient 3: Hereditary Spherocytosis Phenotype
This male was delivered vaginally to a healthy 36-yearold Caucasian G5P3003 at 35 5/7 weeks gestation. Apgar scores were 8 and 9, birth weight was 2905 g. He appeared well, had no dysmorphic features, and was cared for, breastfeeding, in the well-baby nursery and then discharged home about 48 hours after birth. Because jaundice was apparent on day 5, his bilirubin level was checked and was 22.7 mg/dL. He was rehospitalized for intensive phototherapy.
On hospital readmission his hematocrit was 43.5%, hemoglobin 14.2 g/dL, MCHC 32.6 g/dL, MCV 101.9 fL (Table 3) . Twenty hours later his hematocrit was 36.5% and hemoglobin was 11.9 g/dL. Infant and mother were both blood group A positive and the infant's Coombs test was negative.
Quantitative G6PD was normal for the age (24.0 U/g Hgb; reference range 9.9-16.6) and so was the pyruvate kinase level (10.3 U/g Hgb, reference range 4.6-11.2). Hemolysis was documented by several parameters including an elevated end tidal CO of 4.8 ppm (reference range for 7-day old, ≤1 ppm), 8 a haptoglobin level below the lower limit of assay detection (<8 mg/dL), and hemoglobinuria in the absence of RBC in the urine. 9 Reticulocyte count was initially 3.05% (103 000/µL) but 16.30% (622 300/µL) when rechecked 5 days later. Hemoglobin electrophoresis revealed 92.1% Hgb F and 7.9% Hgb A and no abnormal hemoglobin was detected.
His initial blood smear examination revealed the presence of microspherocytes, many schistocytes, bite, and blister cells. Heinz bodies were prominent on supravital stain. DNA sequencing of the gamma globin genes excluded the diagnosis of hemoglobin F Pool, 10 and did not identify any other mutations.
He remained on phototherapy for a total of 12 days in the hospital and 7 additional days at home. He received a RBC transfusion (15 mL/kg) on day of life 9 when his hematocrit was 22.2%. At 10 weeks his hematocrit was 24.4%, hemoglobin 8.2 g/dL, MCHC 33.6 g/dL, MCV 83 fL, reticulocytes 3.7% (108 900/µL), and his blood smear had no bite or blister cells and no Heinz bodies on supravital stain, but prominent spherocytosis persisted (Figure 3) .
Methods
"Next-generation" DNA sequencing (NGS) was performed using a diagnostic panel of genes encoding erythrocyte cytoskeletal proteins, enzymes, and UGT1A1 polymorphisms, including mutations in coding regions, splice site junctions, and deep intronic or regulatory regions (Supplementary Material, available online at http://clp.sagepub.com/supplemental). 4 Targeted gene capture and library construction for sequencing was performed using SureSelect as described by the manufacturer (Agilent Technologies, Santa Clara, CA).
The 2 genetic variations in SPTA1 we found from Patient 1, whose erythrocyte morphology suggested HPP, are shown in Table 4 : (1) A heterozygous pathogenic variant previously reported in patients with hereditary elliptocytosis (c.82C>T, p.Arg28Cys). This was identified in the mother and the proband. (2) A heterozygous variant of uncertain significance (c.5911G>A, p.Asp1971Asn). This was identified in the father and the proband. (3) Mother and father were heterozygous for the UGT1A1*28 promoter polymorphism A(TA) 7 TAA, and the proband was homozygous for this polymorphism.
The 2 genetic variations in SPTA1 we found from Patient 2, whose erythrocyte morphology suggested HS, are shown in Table 4 : (1) Alpha LELY in trans with; (2) a heterozygous novel variant of uncertain significance (c.6421C>T, p.Arg2141Trp). Prediction of the significance of the novel variant, by MutationTaster, 11 was "probably damaging." The proband was also homozygous for the UGT1A1*28 promoter polymorphism A(TA) 7 TAA. The genetic variation in SPTB we found from Patient 3, whose erythrocyte morphology suggested HS, is shown in Table 4 : A heterozygous novel variant of uncertain significance c.3758A>G, p.Glu1253Gly. This same SPTB variant was also found in the father but not in the mother or older sibling. Prediction of the 
Discussion
When we perform DNA sequencing as part of a diagnostic evaluation for congenital hemolytic anemia, we occasionally find variants that are not present in the existing genetic databases. In such cases, we report that the patient has a genetic variant of "uncertain significance." The uncertainty is because we find no previous reports of this exact mutation in a patient with congenital hemolytic anemia. In order to conclude that a genetic variation of "uncertain significance" in SPTA1 or SPTB is indeed the underlying cause of a congenital hemolytic disorder, certain confirmations are needed. First, is there a known association between the gene where the variant is located and a red blood cell morphologic abnormality (genotype-phenotype correlation)? Second, what do in silico predictions conclude regarding whether this variant is likely to be damaging to the erythrocyte cytoskeleton? Third, once a novel variant has been reported in the medical literature, will other investigators identify the same genotype-phenotype combination, thus supporting the speculation that the variant is indeed pathogenic?
In our 3 patients, the variants in SPTA1 and SPTB do seem to fit their erythrocyte morphology. As in our Patient 1, certain SPTA1 variants in trans are known to cause HPP in an autosomal recessive manner. 12 As in our Patient 2, other SPTA1 variants in trans are known to cause HS in an autosomal recessive manner, 6 and as in our Patient 3, certain heterozygous SPTB variants are known to cause HS in an autosomal dominant manner. 6 In our Patient 3, the SPTB variant was paternally inherited and was not identified in the other relatives tested (mother and older female sibling). The identification of this variant in the patient's healthy father does not exclude pathogenicity in the baby, because autosomal dominant inheritance with reduced penetrance is well known in cases of HS due to SPTB mutations. 13 In silico predictions of all 3 novel variants are that these can be damaging to the erythrocyte cytoskeleton. However, confirmation that these 3 variants are indeed pathogenic must await reports of other investigators who find identical genetic spectrin variations in infants with congenital hemolytic jaundice. generation sequencing, and gave final approval. HMY contributed to the conception and design and gave final approval. NSR contributed to the conception and design and gave final approval. EAO contributed to the conception, critically revised the manuscript, and gave final approval. JTP contributed to the conceptin and design, critically revised the manuscript, and gave final approval
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